Image
Recommendation
Anti-HER2 therapy – Combination with chemotherapy
Ideally adjuvant trastuzumab (with or without pertuzumab) should be given concurrently with taxane-based regimens but should not be given concurrently with anthracyclines.
Adjuvant trastuzumab should preferably be given concurrently with taxane-based regimens. It should not be given concurrently with anthracyclines
At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated a 1+, directly applicable to the target population, and demonstrating overall consistency of results
How this guidance was developed
This recommendation was adapted from the NCCP 2015 guidelines (Ireland). The source recommendation was based on a systematic review of the evidence conducted to September 2014 and was graded ‘A’ (using SIGN methods) by the source guideline authors. The source recommendation was adapted by adding ‘with or without pertuzumab’.
Anti-HER2 therapy – Combination with chemotherapy
Recommendation
Ideally adjuvant trastuzumab (with or without pertuzumab) should be given concurrently with taxane-based regimens but should not be given concurrently with anthracyclines.
Principles in action
Safe and quality care
This recommendation was adapted from the NCCP 2015 guidelines (Ireland). The source recommendation was based on a systematic review of the evidence conducted to September 2014 and was graded ‘A’ (using SIGN methods) by the source guideline authors. The source recommendation was adapted by adding ‘with or without pertuzumab’.